Metformin Impedes Oxidation of LDL In Vitro

Metformin is the most commonly prescribed glucose-lowering drug for the treatment of type 2 diabetes. The aim of this study was to investigate whether metformin is capable of impeding the oxidation of LDL, a crucial step in the development of endothelial dysfunction and atherosclerosis. LDL was oxid...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossmann, Christine, Ranz, Cornelia, Kager, Gerd, Ledinski, Gerhard, Koestenberger, Martin, Wonisch, Willibald, Wagner, Thomas, Schwaminger, Sebastian P., Di Geronimo, Bruno, Hrzenjak, Andelko, Hallstöm, Seth, Reibnegger, Gilbert, Cvirn, Gerhard, Paar, Margret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459002/
https://www.ncbi.nlm.nih.gov/pubmed/37631325
http://dx.doi.org/10.3390/pharmaceutics15082111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459002/
https://www.ncbi.nlm.nih.gov/pubmed/37631325
http://dx.doi.org/10.3390/pharmaceutics15082111

Ejemplares similares